

MYM NUTRACEUTICALS INC.

Suite 1500, 409 Granville St.
Vancouver, BC V6C 1T2

FORM 51-102F1

MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) AS OF SEPTEMBER 26, 2017 TO ACCOMPANY THE CONSOLIDATED FINANCIAL STATEMENTS OF MYM NUTRACEUTICALS INC. (THE “COMPANY”) FOR THE YEAR ENDED MAY 31, 2017.

The following Management Discussion and Analysis (“MD&A”) of MYM Nutraceuticals Inc. (the “Company” or “MYM”) has been prepared by management, in accordance with the requirements of National Instrument 51-102 as of September 26, 2017 and should be read in conjunction with the audited annual consolidated financial statements for the years ended May 31, 2017 and 2016, and the related notes contained therein which have been prepared under International Financial Reporting Standards (“IFRS”). The information provided in this document is not intended to be a comprehensive review of all matters and developments concerning the Company.

All financial information in this MD&A has been prepared in accordance with IFRS and all dollar amounts are quoted in Canadian dollars, the reporting and functional currency of the Company, unless specifically noted.

This MD&A contains certain forward-looking statements based on the best beliefs, and reasonable assumptions of the management of the Company. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. (See “Risks and Uncertainties” in this MD&A for more information).

Overall Performance and Description of Business

MYM Nutraceuticals Inc. (the “Company” or “MYM”), a publicly traded company listed on the Canadian Securities Exchange under the symbol:MYM, was incorporated pursuant to the Business Corporations Act of British Columbia (“BCABC”) on July 11, 2014, under incorporation number BC1002050. The Company’s head office is located at Suite 1500 - 409 Granville Street, Vancouver, British Columbia, Canada, and the Company’s registered and records office is located at 10th Floor – 595 Howe Street, Vancouver, British Columbia, V6C 2T5.

The Company has five wholly owned subsidiaries, Joshua Tree Brands Inc - previously-Adera Minerals Corp. (“Adera”) incorporated pursuant to the BCABC on February 18, 2011 under incorporation number BC 0903363 and My Marijuana Natural Resources Inc. (“MMNR”), MYM Holdings Inc. (“MYMH”), incorporated on May 14, 2014 and May 16, 2014 (BCABC), 1114865 B.C. Ltd. incorporated on April 11, 2017 (BCABC) and MYM Holdings (WA) Inc. (“MYMWA”) incorporated in the State of Washington on June 1, 2016.)

The Company is in the business of acquiring and developing natural remedies and currently holds the rights to various intangible assets including intellectual property, domain names and copyrights, customer lists, and a Marijuana for Medicinal Purposes Regulation (“MMPR”) Licensing application through its wholly owned subsidiaries.

In February 2017, the Company announced it had completed the acquisition of a fifty-one percent majority interest in Sublime Culture Inc. (“Sublime”) and its inspection-stage application to become a Licensed Producer of medical cannabis. The Company plans to continue funding the build out Sublime’s production facility in Laval, Quebec in preparation for inspection by Health Canada. The anticipated costs to December 31, 2017 are approximately \$2 million. The Company hopes to get the ACMPR license approval by December 31, 2017.

MYM NUTRACEUTICALS INC.

In April 2017, the Company announced that it has completed the acquisition of 100% of the brand and assets of "HempMed," a Toronto-based developer and marketer of hemp-based cannabidiol "CBD" extracts and oil infused nutraceutical products. The Company is in the process of rebranding the HempMed products under its new brand JoshuaTree and expects to launch the new brand before December 2017. Revenues for these products are currently averaging approximately \$100,000 per month.

In June 2017, the Company announced that it had entered into an exclusive deal with the Municipality of Weedon, Quebec to build a 1.5 million-square-foot medical cannabis facility consisting of fifteen 100,000-square-foot greenhouses. The agreement was signed by a new subsidiary CannaCanada Inc. that is initially 75% owned by the Company.

In September 2017, the Company announced that it has entered an Asset Purchase and Consulting Agreement (the "**Agreement**") with 9609989 Canada Inc. (d.b.a. Mary Jane's Touch "MJT"), which manufactures and distributes cannabidiol (CBD) and CBD products derived primarily from hemp, and possesses numerous formulations of CBD products and research on CBD and its principals, MJT has been supplying CBD to MYM's subsidiary, Joshua Tree ("JT"), for use in Joshua Tree's products. MYM has acquired MJT's intellectual property and other assets to continue to develop its innovative nutraceutical products. The Company expects to start deriving revenue from this agreement effective October 1, 2017.

The company plans to invest up to \$500,000 on equipment and technologies to expand the manufacturing capabilities of MJT to meet the forecast needs of its Joshua Tree Brands.

Although the Company has started to invest resources for a medical marijuana business, there is no guarantee the Company will be awarded a license to grow medical marijuana nor is there a time frame available as to when the Company will be notified of the success of its application.

The Company is continuing to explore other potential acquisitions and opportunities in the nutraceuticals space.

As at the date of this report, the Company has sought and received approval for a listing on the Over-the-Counter Market (OTC) in the US. and has received Depositor Trust Company (DTC) eligibility for its shares so they can be held at DTC and traded and serviced through DTC's electronic book-entry system. Our OTC trading symbol is MYMMF

Results of Operations

Results of Operations – For the year ended May 31, 2017

For the year ended May 31, 2017 the Company incurred a loss of \$894,317, as compared to \$1,046,570 for the same period in 2016. The Company reported revenues in the current year of \$142,565 (2016: Nil) and gross profit of \$63,993 (2016: \$Nil) from sales of HempMed assets in the last two months of the year. General and administrative expenses increased from \$326,482 in 2016 to \$880,790 in 2017. Consulting fees increased from \$18,524 in 2016 to 216,928 in 2017 as the company brought in additional resources to assist with the OTC listing and DTC Compliance and additional support for the Sublime and HempMed operations. Professional fees increased from \$32,699 to \$74,891 reflecting additional legal and accounting services required for the acquisitions. Rent incurred for the year ended May 31, 2017 was \$41,657 (2016: \$Nil) for the HempMed office space and the Sublime operating lease in Laval. Salaries and Management fees increased from \$65,500 in 2016 to \$90,156 in 2017 due to the hiring of the new CEO. A non-cash finders fee of \$184,000 was recorded for shares issued in connection with the HempMed acquisition.

The fair value of options and shares granted and vested to certain key directors, management and consultants vested were valued at \$135,045 (2016:\$119,546) using the Black Scholes valuation model.

MYM NUTRACEUTICALS INC.

During the year ended May 31, 2017, the company recorded acquisition costs of \$65,000 (2016: \$Nil) for the Sublime acquisition and recorded a writedown of \$1,500 (2016: \$432,200) on intangible assets. During 2017, the Company recorded a loss on the sale of land \$Nil (2016: \$96,508) and a writedown of deposits of \$15,000 (2016: \$191,380)

Results of Operations – For the three months ended May 31, 2017

For the three months ended May 31, 2017 the Company incurred a loss of \$695,039 as compared to \$713,447 for the same period in 2016. The Company reported revenues for the quarter of \$142,565 (2016: Nil) and gross profit of \$63,993 (2016: \$Nil) from sales of HempMed assets in the last two months of the year. General and administrative expenses increased from \$89,867 for the quarter in 2016 to \$681,512 in 2017. Consulting fees increased from (\$10,726) in 2016 to \$141,366 in 2017 as the company brought in additional resources to assist with the OTC listing and DTC Compliance and additional support for the Sublime and HempMed operations. Professional fees increased from \$16,537 to \$71,568 reflecting additional legal and accounting services required for the acquisitions. Rent incurred for the quarter ended May 31, 2017 was \$41,657 (2016: \$Nil) for the HempMed office space and the Sublime operating lease in Laval Salaries and Management fees increased from \$13,500 in 2016 to \$38,156 in 2017 due to the hiring of the new CEO and an increase in fees. A non-cash finders' fee of \$184,000 was recorded for shares issued for the HempMed acquisition in 2017.

During the three months ended May 31, 2017, the company recorded acquisition costs of \$65,000 (2016: \$Nil) for the Sublime acquisition and recorded a writedown of \$1,500 (2016: \$432,200) on intangible assets. The Company recorded a loss on the sale of land \$Nil (2016: \$96,508) and a writedown of deposits of \$15,000 (2016: \$191,380).

Summary of quarterly results

	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
	May 31	February	November	August 31	May 31	February	November	August 31
	2017	2017	2016	2016	2016	2016	2015	2015
Net Loss	(\$695,039)	(\$100,174)	(\$40,652)	(\$58,452)	(\$713,447)	(\$182,117)	(\$105,519)	(\$45,487)
Loss per share	(\$0.01)	(\$0.00)	(\$0.00)	(\$0.00)	(\$0.01)	(\$0.00)	(\$0.00)	(\$0.00)

The main factors causing significant fluctuations in Net Loss from quarter to quarter were as follows:

- *Revenues.* During the quarter ended May 31, 2017, the Company started to receive revenues on the sale of CBD products thru its HempMed acquisition.
- *Finders' fee.* During the quarter ended May 31, 2017, the Company recorded a non-cash finders' fee of \$184,000 for the issuance of stock for the HempMed acquisition.
- *Management fees.* During the quarter ended August 31, 2016, management fees were increased by \$1,500 per quarter to reflect the additional efforts of the team. During the quarter ended February 28, 2017, management fees were increased by \$8,500 to provide for the increasing duties various officers and directors of the company. During the quarter ended May 31, 2017, the Company hired a new CEO increasing the quarterly costs.
- *Rent.* During the quarter ended May 31, 2017 the Company incurred rent for the new operations of Sublime and HempMed.
- *Writedown of Assets.* During the quarter ended February 29, 2016, the company recorded an

MYM NUTRACEUTICALS INC.

impairment charge of \$96,508 on the property in Maple Ridge. During the quarter ended May 31, 2016, the company recorded impairment of intangible assets and a writedown on deposits on land for a total of \$623,580. In May 2017, the Company recorded acquisition costs of \$65,000 for the HempMed acquisition.

- *Stock based compensation.* During the quarters ended November 30, 2015, February 29, 2016, May 31, 2016, August 31, 2016, November 30, 2016, and February 2017, and May 2017 the Company recorded expenses for the granting of options to certain key directors, officers, and consultants. The amounts recorded were calculated using the graded vesting method.
- *Interest Expenses.* Interest expenses during the quarter ended August 31, 2016 and February 2017 are reduced from prior quarters as various loans were paid back.
- *Writedown of deposits.* During the quarter ended August 31, 2015, the Company expensed \$15,000 on the Oroville property.
- *Consulting Fees.* During the quarter ended February 2017 increased consulting fees were incurred with the onboarding of a European Markets advisor. During the quarter ended May 31, 2017, additional costs were incurred obtaining an OTC listing and DTC compliance in the US and additional consulting services related to the HempMed and Sublime operations.
- *Professional Fees.* During the quarter ended May 31, 2017, increased legal and accounting fees were incurred due to the Sublime and HempMed acquisitions.

Selected Annual Information

The following tables show selected summary consolidated financial information which have been derived from the consolidated annual financial statements of the Company at May 31, 2017, 2016 and 2015, which have been prepared in accordance with IFRS.

		Year ended	
	May 31, 2017	May 31, 2016	May 31, 2015
Operating Revenue	\$ 142,565	0	0
Net income (loss)	\$ (894,317)	(1,046,570)	(712,684)
Income (Loss) per share	\$ (0.01)	(0.02)	(0.01)
Share capital	\$ 3,051,623	1,644,748	1,446,600
Common shares issued	67,981,429	53,300,001	47,370,001
Weighted average shares outstanding	57,296,128	49,777,056	48,524,960
Total Assets	\$ 1,768,366	159,122	1,347,225
Total Equity (Deficit)	\$ 1,511,703	(198,961)	504,390

Project Summaries and Activities

Medical Marijuana Licensing Application - Laval

On February 22, 2017, the Company announced the completion of the acquisition of a fifty-one percent majority interest in Sublime Culture Inc. (“Sublime”) and its inspection-stage 6 of 7 stages application to become a Licensed Producer of medical cannabis in Quebec. The Company issued 1,000,000 shares of common stock at \$0.065 per share for a total value of \$65,000 for the acquisition. The Company will be required to raise between \$1,800,000 and \$2,500,000 to fund the completion and operation of the facility.

Anticipating approval of the application, Sublime entered into a lease agreement for a production facility in Laval, Quebec and on September 26, the Company announced that it has finalized the lease agreement on building space for expansion into Phase B of the Laval, QC project. Effective October 1, 2017 MYM will take possession of additional facility space adjacent to the currently leased, Phase A facility. The addition of the new lease increases the total facility space of the Laval, QC project from 10,000 square feet to 26,000 square feet including a mezzanine to be built. The expansion will triple the total production capacity of the Laval facility. Engineering plans for Phase B will be submitted to the Government of Laval by November 1, 2017. Expansion plans will subsequently be submitted to Health Canada to include the Phase B facility under the Phase A license that is currently under consideration.

Obtaining a production license under the Access to Cannabis for Medical Purposes Regulations will significantly accelerate the launch of the Company’s innovative brand of cannabis-infused nutraceutical products. MYM will also be able to leverage Sublime's expertise and connections in Eastern Canada, as well as bring on key personnel to facilitate future growth. Key benchmarks with respect to maximizing production space and the purchase of the property were established, and plans are now underway to stage the build-out of the entire building with the inclusion of a roof-top greenhouse that will maximize the total production canopy to 26,000 square feet. The Company intends to pursue the purchase of the land and, upon successful inspection and issuance of a license, start the additional build-outs, thereby allowing the Company to own up to 90% of Sublime Culture Inc. and 100% of the production facility. This will allow the Company to meet the demands it expects from its ever-growing client patient list and create even more shareholder value.

The Company is looking to lead the Canadian market by establishing the gold standard in quality assurance testing of its cannabis products. The Company has engaged TheraCann International Benchmark Corp (TheraCann) to implement its full suite of services including ISO 17025(2005) compliance to ensure repeatable and reliable data stands behind each product label. TheraCann will also be providing TheraCann SYSTEM software to the Company which directly captures all testing and analysis data to better control regulatory compliance concerns and future audits by Health Canada.

With the recent announcement that the Canadian Provinces to be able to decide how cannabis will be distributed within their borders, the federal government will oversee all medical and recreational marijuana cultivation. The Company is planning to jump ahead of the curve on future legislation to focus on in-house quality assurance testing laboratories and analytics.

Medical Marijuana Licensing Application - Weedon

In June 2017, the Company announced that it had entered into an exclusive deal with the Municipality of Weedon, Quebec to build a 1.5 million-square-foot cannabis facility consisting of fifteen 100,000-square-foot greenhouses. The agreement was signed by a new subsidiary CannaCanada Inc. that is initially 75% owned by the Company. As at the date of this report, the Company has submitted its application to Health Canada for a license under the *Access to Cannabis for Medical Purposes Regulations* (or ACMPR)

Manufacturing and distribution of hemp-based nutraceutical products

On April 11, 2017, the Company announced that it has completed the acquisition of 100% of the brand and assets of "HempMed," a Toronto-based developer and marketer of hemp-based CBD extracts and oil infused nutraceutical products. Pursuant to the Acquisition Agreement between the Company and HempMed, the Company issued 2,500,000 MYM shares to the owner of HempMed, and a further 1,500,000 will be issued upon reaching certain monthly and annual sales targets. The fast growing HempMed brand is forecasting sales in excess of \$1,400,000 over in the next 12 months.

The Company has plans to build a new high-capacity production facility for HempMed that will increase its sales capacity to handle more than \$10,000,000 per year. Further, the Company will open new markets and build an effective online retail strategy for the already popular HempMed brand. The Company has plans to rebrand the entire line of products including upgrading manufacturing facilities for large-scale production capabilities. Online sales and marketing will be a major focus to accelerate worldwide expansion of CBD product sales. With the additional support both financially and professionally the Company believes the CBD product line will be one of its top performers.

The Company has retained the senior staff and founder of HempMed on contract for a minimum of 3 years to drive success within the billion-dollar industry. The CBD nutraceutical market is growing rapidly worldwide due to an explosion of consumer interest and impressive medical studies on the benefits of high quality hemp CBD products. A recent Forbes magazine article estimated that the CBD market will grow to \$2.1 billion market by 2020 with \$450 million of those sales coming from hemp-based sources. That's a 700% increase from 2016.

The current HempMed product line currently consists of over 20 Hemp products and includes signature tinctures, concentrates and oils, edibles, vape products and a line of fast growing pet CBD products, which will join the multi-billion-dollar pet market. CBD hemp oil and hemp-based nutraceuticals have been some of the strongest components of the cannabis industry. HempMed has developed proprietary technology that allows their CBD products to be not only very effective but of the highest quality and consistency.

The Company has high expectations for this business division and we will be investing substantial capital in sales and marketing platforms that will engage a wide range of people who are looking for alternative organic plant based products capable of aiding in the relief multiple ailments with little or no side effects.

Conclusions

Until the Company successfully obtains a license from Health Canada to produce medical marijuana or the laws in Canada change to permit the use of cannabis for recreational purposes, we will continue to engage in business activities that can generate revenue in related markets. The Company will focus on the development of hemp products to ensure an easy transition into cannabis products. The Company will continue to build on its existing relationships while building new relationships with other small emerging companies. The Company believes there are other companies who share our same vision and are willing to unite to help form a collective that can pool resources and contacts to produce formidable businesses in the cannabis space. MYM is continuing to negotiate acquisitions of complementary businesses and assets in the technology, nutraceuticals and CBD nutraceutical sectors and is currently in talks with other innovative companies.

Outstanding Share Data

The Company has an authorized share capital of an unlimited number of common shares, of which 83,679,977 were issued as at the date of this report. In addition, the company has 10,432,120 share purchase warrants outstanding and 7,365,000 incentive stock options granted of which 4,102,500 are fully vested as at the date of this report.

Related Party Transactions

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members.

The aggregate value of transactions relating to key management personnel were as follows:

	YEAR ENDED	
	MAY 31	
	2017	2016
Salaries and benefits, consulting and management fees	\$ 132,156	\$ 104,500
Real estate commission paid to Director	-	14,785
Stock-based compensation	135,049	117,844
Total Salaries and other short term benefits	<u>\$ 267,205</u>	<u>\$ 237,129</u>

As at May 31, 2017, \$1,004 (2016 - \$93,175) were owing to key management personnel or to a company controlled by a director or key management personnel and the amounts were included in due to related parties. The amounts payable are non-interest bearing, are unsecured, and have no specific terms of repayment.

During the year ended May 31, 2016, the company issued 1,500,000 shares in settlement of due to related parties in the amount of \$30,000 to a director and officer of the corporation for past services.

As at May 31, 2017, the total loans due to related parties were \$Nil (May 31, 2016 - \$165,000). The balance of interest payable is \$Nil (May 31, 2016 – \$11,373) (Note 8).

Liquidity and Solvency

The following table summarizes the Company's cash on hand, working capital and cash flow:

As at	May 31, 2017	May 31, 2016
Cash	\$ 548,514	\$ 145,156
Working capital (deficiency)	370,274	(204,846)
Year ended	May 31, 2016	May 31, 2016
Cash (used in) operating activities	\$ (670,592)	\$ (64,999)
Cash provided by (used in) investing activities	(41,456)	570,920
Cash (used in) provided by financing activities	1,115,406	(382,946)
Change in cash	<u>\$ 403,358</u>	<u>\$ 122,975</u>

The Company is dependent on the borrowing of cash and the issuance of shares to finance its activities, property acquisition payments and general and administrative costs. The Company will have to raise additional funds in the future to continue its operations. There can be no assurance, however, that the Company will be successful in its efforts. If such funds are not available or other sources of financing cannot be obtained, then the Company will be forced to curtail its activities.

Capital Resources

The Company has minimal operations to generate cash flow and its long term financial success will be dependent on the Company's ability to obtain equity financing.

The Company's next immediate step in development is to raise the capital required to continue its investment in the Sublime and HempMed opportunities. The Company will continue to explore the other initiatives management has or may identify.

The Company has not pledged any of its assets as security for loans, or otherwise is not subject to any debt covenants.

Off-Balance Sheet Arrangements

NA

Proposed Transactions

The Company does not have any proposed transactions

Critical Accounting Judgements and Estimates

During the year the Company generated revenues, some of which may be subject to collectivity. The Company assesses the collectability of receivables on an ongoing basis. A provision for the impairment of receivables involves significant management judgment and includes the review of individual receivables based on individual customer creditworthiness, current economic trends and analysis of historical bad debts. As this is a new process for the Company, and given that all sales are currently on a cash basis, the amounts recorded as bad debts for the current year are based on actual collection results.

Changes in Accounting Policies

During the year the company implemented the following new policies based one newly acquired operations.

Inventories

Finished products, work in-process, raw materials and supplies inventories are valued at the lower of weighted average cost and net realizable value. Raw materials include CBD concentrates. Work in process inventory includes inventory in held by 3rd party manufacturers. For work in-process and finished product inventories, cost includes all direct costs incurred in production, including direct labour and materials, freight, depreciation and amortization and directly attributable overhead costs. When inventories have been written down to net realizable value, we make a new assessment of net realizable value in each subsequent period. If the circumstances that caused the write-down no longer exist, the remaining amount of the write-down is reversed. Supplies inventory is valued at the lower of weighted average cost and net realizable value. Cost includes acquisition, freight and other directly attributable costs.

Goodwill

The Company allocates goodwill arising from business combinations to each (cash-generating unit, or "CGU") or group of CGUs that are expected to receive the benefits from the business combination. The carrying amount of the CGU or group of CGUs to which goodwill has been allocated is tested annually for impairment or when there is an indication that the goodwill may be impaired. Any impairment is

MYM NUTRACEUTICALS INC.

recognized as an expense immediately. Should there be a recovery in the value of a CGU, any impairment of goodwill previously recorded is not subsequently reversed.

Revenue Recognition

Sales of product, including by-product, are recognized in revenue when there is persuasive evidence that all of the following criteria have been met: the significant risks and rewards of ownership pass to the customer, neither continuing managerial involvement nor effective control remains over the goods sold, the selling price and costs to sell can be measured reliably, and it is probable that the economic benefits associated with the sale will flow to us. All of these criteria are generally met by the time the significant risks and rewards of ownership pass to the customer.

Business combination

At the time of acquisition of property, the Company considers whether the acquisition represents the acquisition of a business. The Company accounts for an acquisition as a business combination where an integrated set of activities is acquired in addition to the property.

The cost of a business combination is measured as the aggregate of the consideration transferred at acquisition date fair value. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at fair value at the acquisition date. The Company recognizes any contingent consideration to be transferred by the Company at its acquisition date fair value. Goodwill is initially measured at cost, being the excess of the purchase price over the fair value of the net identifiable assets acquired and liabilities assumed. Acquisition-related costs are expensed in the period incurred.

The following new standards were adopted during the year ended May 31, 2017:

- i) *IAS 27: Amended to restore option to use equity method to account for investments in subsidiaries, joint ventures and associates for annual period beginning on or after January 1, 2016.*

Certain other pronouncements were adopted by the Company on June 1, 2016, none of which had a significant impact on the Company's consolidated financial statements.

The following new standards, and amendments to standards and interpretations, are not yet effective for the current period and have not been applied in preparing these financial statements. Some updates that are not applicable or are not consequential to the Company may have been excluded from the list below

- ii) *IFRS 9: New standard that replaced IAS 39 for classification and measurement, tentatively effective for annual periods beginning on or after January 1, 2018.*
- iii) *Partial replacement of IAS 39 Financial Instruments: Recognition and Measurement. This standard is effective for annual periods beginning on or after January 1, 2018. The Company is currently evaluating the impact of this standard.*
- iv) *IFRS 15 deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. Revenue is recognized when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good or service. The standard replaces IAS 18 'Revenue' and IAS 11 'Construction contracts' and related interpretations.*
- v) *IFRS 16, "Leases", was issued in January 2016, and replaces IAS 17, "Leases" ("IAS 17"). IFRS 16 eliminates the classification of leases as either operating leases or finance leases as is required by IAS 17 and, instead, introduces a single lessee accounting model. Certain leases will be exempt from these requirements. IFRS 16 is effective for periods beginning on or after January 1, 2019.*

Financial Instruments

The Company is exposed in varying degrees to a number of risks arising from financial instruments. Management's close involvement in the operations allows for the identification of risks and variances from expectations. The Company does not participate in the use of financial instruments to mitigate these risks and has no designated hedging transactions. The Board approves and monitors the risk management processes. The Board's main objectives for managing risks are to ensure liquidity, the fulfillment of obligations, the continuation of the Company's exploration activities, and limited exposure to credit and market risks. There were no changes to the objectives or the process from the prior period.

The types of risk exposure and the way in which such exposures are managed are as follows:

a) Credit Risk

Credit risk primarily arises from the Company's cash and cash equivalents and amounts receivable. The risk exposure is limited to their carrying amounts at the statement of financial position date. Cash and cash equivalents are held as cash deposits or invested in guaranteed investment certificates with various maturity dates. The Company does not invest in asset-backed deposits or investments and does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the bank and the investment grade of the guaranteed investment certificates.

b) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company ensures there is sufficient capital to meet short term business requirements. One of management's goals is to maintain an optimal level of liquidity through the active management of assets, liabilities and cash flows.

The Company's cash and cash equivalents are deposited in major banks or invested in guaranteed investment certificates, which are available on demand to fund the Company's operating costs and other financial demands.

c) Market Risk

The significant market risks to which the Company is exposed are currency and interest rate risk.

i) Currency Risk

The operating results and financial position of the Company are reported in Canadian dollars. As the Company is exploring opportunities in an international environment, some of the Company's financial instruments and transactions are denominated in currencies other than the Canadian dollar. The results of the Company's operations are subject to currency risk.

Many of the Company's costs are incurred in Canada and are denominated in Canadian dollars. Foreign currency transactions are booked at historical cost in Canadian dollars.

As at May 31, 2017, the Company is not exposed to any currency risk.

ii) Interest Rate Risk

The Company's policy is to invest excess cash in guaranteed investment certificates at fixed or floating rates of interest and cash equivalents are to be maintained in floating rates of interest in order to maintain liquidity, while achieving a satisfactory return for shareholders. As at May 31, 2017 no cash was held in interest bearing deposits. Fluctuations in interest rates impact the value of cash and cash

equivalents. The Company manages risk by monitoring changes in interest rates in comparison to prevailing market rates.

Currently, the Company believes that it is not exposed to significant interest, currency or credit risks arising from its financial instruments.

Risks and Uncertainties

Although the Company believes it is a good candidate for a ACMPR Production License, it is uncertain and not foreseeable whether the Company will be able to meet the new requirements and be granted such a license. Denial of the Company's application for a Production License is reasonably expected to materially affect the Company's business, financial condition and operations.

Subsequent Events

On September 26, 2017, the Company announced a new private placement of up to 6,000,000 units to be offered at a price of \$0.50 per unit for gross proceeds of \$3,000,000. Each unit consists of one common share and one transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable for one year at a price of \$1.00 per warrant share. Finders' fees up to 7.5% may be paid on this placement. The issuance of any shares or warrants are subject to approval of the regulatory authorities. Proceeds from this placement will be used to fund the Laval buildout for operation, the expansion of the CBD manufacturing operations and general working capital.

Other

Additional information relating to the Company's operations and activities can be found by visiting: www.sedar.com.

Cautionary Statement

This document contains "forward-looking statements" within the meaning of applicable Canadian securities regulations. All statements other than statements of historical fact herein, including, without limitation, statements regarding exploration plans and our other plans and objectives are forward-looking statements that involve various risks and uncertainties. Such forward-looking statements include, without limitation, statements with respect to expectations, projections, or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. There can be no assurance that such statements will prove to be accurate, and future events and actual results could differ materially from those anticipated in such statement. Important factors that could cause actual results to differ materially from our expectations are disclosed in the Company's documents filed from time to time via SEDAR with the Canadian regulatory agencies to whose policies we are bound. Forward-looking statements are based on the estimates and opinions of management on the date of statements are made, and the Company endeavours to update corporate information and material facts on a timely basis. Forward-looking statements are subject to risks, uncertainties and other actors, including risks associated with assumptions and certain factors regarding, among other things: future cannabis pricing; cannabis production yields; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; the regulatory requirements; the application of federal and provincial environmental laws; the ability to enter and participate in international opportunities, and the impact of increasing competition and operational and political risks. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this MD&A, and except as required by applicable law, The Company undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.